Meeting
2022 ASCO Annual Meeting
Efficacy and safety of nivolumab for locally advanced or metastatic cutaneous cell carcinoma (NIVOSQUACS trial).
Authors
Roland Lang
Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria
Roland Lang , Peter Koelblinger , Erika Richtig , Ingrid Wolf , Christoph Hoeller , Christine Hafner , Van Anh Nguyen , Julian Kofler , Matthias Barta , Wolfgang Hitzl , Martin Laimer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04204837
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9528)
DOI
10.1200/JCO.2022.40.16_suppl.9528
Abstract #
9528
Poster Bd #
121
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
First Author: Makoto Ueno
Poster
2023 ASCO Annual Meeting
Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.
First Author: Neal Shiv Chawla
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety of nivolumab for malignant mesothelioma in the real world.
First Author: Koji Mikami
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.
First Author: Sant P. Chawla